Lopez SJ - Search Results

1

Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease.

Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y, Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R. Tamaki N, et al. Among authors: lopez sj. J Clin Invest. 2022 Nov 1;132(21):e162513. doi: 10.1172/JCI162513. J Clin Invest. 2022. PMID: 36317632 Free PMC article.

2

Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.

Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, Zamani A, Lopez S, Mangla N, Bettencourt R, Rizo E, Valasek M, Behling C, Richards L, Sirlin C, Loomba R. Ajmera VH, et al. Hepatology. 2020 Mar;71(3):849-860. doi: 10.1002/hep.30974. Epub 2020 Jan 27. Hepatology. 2020. PMID: 31556124 Free PMC article.

3

Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.

Park JG, Jung J, Verma KK, Kang MK, Madamba E, Lopez S, Qas Yonan A, Liu A, Bettencourt R, Sirlin C, Loomba R. Park JG, et al. Aliment Pharmacol Ther. 2021 May;53(9):1030-1037. doi: 10.1111/apt.16324. Epub 2021 Mar 25. Aliment Pharmacol Ther. 2021. PMID: 33764550 Free PMC article.

4

Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.

Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, Bettencourt R, Jung J, Gitto Z, Hernandez C, Lopez SJ, Gupta H, Sirlin CB, Marks RM, Loomba R. Huang DQ, et al. Among authors: lopez sj. Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844. Epub 2022 Feb 28. Aliment Pharmacol Ther. 2022. PMID: 35229334 Free PMC article.

5

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. Ajmera V, et al. J Hepatol. 2023 Mar;78(3):471-478. doi: 10.1016/j.jhep.2022.11.010. Epub 2022 Nov 19. J Hepatol. 2023. PMID: 36410554 Free PMC article.

6

Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study.

Huang DQ, Ahlholm N, Luukkonen PK, Porthan K, Amangurbanova M, Madamba E, Bettencourt R, Siddiqi H, Cervantes V, Hernandez C, Lopez SJ, Richards L, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R. Huang DQ, et al. Among authors: lopez sj. Clin Gastroenterol Hepatol. 2024 Jan;22(1):81-90.e4. doi: 10.1016/j.cgh.2023.06.020. Epub 2023 Jul 3. Clin Gastroenterol Hepatol. 2024. PMID: 37406954 Free article.

7

Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes.

Kuo SZ, Cepin S, Bergstrom J, Siddiqi H, Jung J, Lopez S, Huang DQ, Taub P, Amangurbanova M, Loomba R. Kuo SZ, et al. Aliment Pharmacol Ther. 2023 Sep;58(6):585-592. doi: 10.1111/apt.17637. Epub 2023 Jul 11. Aliment Pharmacol Ther. 2023. PMID: 37431679 Free PMC article.

8

Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.

Ajmera V, Tesfai K, Sandoval E, Lopez S, Cervantes V, Madamba E, Bettencourt R, Manousou P, Richards L, Loomba R. Ajmera V, et al. Hepatology. 2024 May 1;79(5):1098-1106. doi: 10.1097/HEP.0000000000000635. Epub 2023 Oct 20. Hepatology. 2024. PMID: 37862551

9

Predictors of Occlusion after Carotid Stenting.

Rothenberg P, Lopez SJ, Thibault D, Pillai L, Minc SD. Rothenberg P, et al. Among authors: lopez sj. Ann Vasc Surg. 2024 May;102:172-180. doi: 10.1016/j.avsg.2023.11.045. Epub 2024 Feb 1. Ann Vasc Surg. 2024. PMID: 38307227

10

CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II.

Lopez SJ, Williams HJ, Hogan TF. Lopez SJ, et al. Urol Case Rep. 2023 May 12;50:102421. doi: 10.1016/j.eucr.2023.102421. eCollection 2023 Sep. Urol Case Rep. 2023. PMID: 37719181 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page